Travere Therapeutics (TVTX)CFO sold ~$104K
Christopher R. Cline, CFO at Travere Therapeutics, sold ~$104K of Travere Therapeutics shares.
- ~$104K
- Approx. value · 5,192 sh @ $20.12
- 90K
- Holds after · shares reported
- Traded
- Feb 3, 2025
- Filed
- Feb 5, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 26, 2024InsiderOfficer sold ~$258K of TVTX shares in the open market
- Jan 3, 2025InsiderOfficer sold ~$39K of TVTX shares in the open market
- Jan 6, 2025InsiderOfficer sold ~$8.3K of TVTX shares in the open market
- Jan 22, 2025Insider · 6 peopleInsiders: 6 sales (~$368K)
- Jan 23, 2025InsiderDirector sold ~$320K of TVTX shares in the open market
- Feb 3, 2025 · this disclosureInsiderCFO sold ~$104K of TVTX shares in the open market
What came next
- Feb 3, 2025Insider · 6 peopleInsiders: 6 sales (~$1.6M)
- Feb 4, 2025InsiderOfficer sold ~$21K of TVTX shares in the open market
- Feb 6, 2025InsiderDirector sold ~$220K of TVTX shares in the open market
- Feb 11, 2025Insider · 3 peopleInsiders: 7 sales (~$1.7M)
- Feb 12, 2025Insider · 4 peopleInsiders: 4 sales (~$431K)
- Apr 11, 2025InsiderCFO sold ~$631 of TVTX shares in the open market
- May 5, 2025Insider · 5 peopleInsiders: 5 sales (~$644K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Travere Therapeutics
For Travere Therapeutics, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TVTX page.
Other recent filings by Christopher R. Cline, CHIEF FINANCIAL OFFICER
- SEC Form 4 at Travere Therapeutics (TVTX)Sep 5, 2025
- SEC Form 4 at Travere Therapeutics (TVTX)Sep 5, 2025
- SEC Form 4 at Travere Therapeutics (TVTX)Aug 28, 2025
- SEC Form 4 at Travere Therapeutics (TVTX)May 6, 2025
- SEC Form 4 at Travere Therapeutics (TVTX)Apr 14, 2025
The full history of Christopher R. Cline, CHIEF FINANCIAL OFFICER is on the profile page.
How this filing works
Explore the data
Other disclosures at Travere Therapeutics
- SEC Form 4Oct 19, 2026
- SEC Form 4Oct 19, 2026
- SEC Form 4Oct 19, 2026
- SEC Form 144Oct 15, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its TVTX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
